Dr. Gustavo Mahler joins Dynamk Capital as a Managing Partner after leaving his 10year tenure with AGC Biologics (formerly CMC Biologics), and previously as a Venture Partner with Dynamk. Under his leadership as CEO of AGC Biologics, the company grew to become a leader in biologics contract development and manufacturing with operations in the United States, Europe, and Asia.
Gustavo comes to Dynamk Capital with a wealth of industry knowledge specifically related to the development and commercialization of biologics and has been an Advisor to the fund since inception. While at AGC Biologics, he successfully supported clients from pre-clinical through commercial production for over 150 biologics programs, while successfully guiding customers through the regulatory approval processes.Gustavo was a key player in the sale of CMC Biologics to the Asahi Glass Corporation for EUR 520 million in 2017.
Throughout his career, which also included a role as VP Technical Operations at Bayer Healthcare, Gustavo has been involved in all aspects of biomanufacturing including large scale cell culture and protein manufacturing, purification, solid and liquid formulation including aseptic filling, and facility operation under cGMP guidelines. He has a real-life understanding of the challenges facing biomanufacturers and the implementation of tools, technologies, and services to address them.
His insights are invaluable as part of the team at Dynamk Capital evaluating new technologies and guiding companies in Dynamk’s growing portfolio.Gustavo holds a Ph.D. in Biochemistry from the University of Buenos Aires and an MBA from the University of Madrid and has attended MIT Sloan School of Management Executive Education Courses in Leadership & Management.
MIT Sloan School of Management, Executive Education
Leadership and Management
University of Madrid
Master of Business Administration
University of Buenos Aires
M.Sc., B.Sc., Biochemistry